Eli Lilly and Innovent Biologics reach commercialization agreement for Jepali (pitubutinib tablets) in mainland China

2024-12-16 09:10:56

On December 16, Eli Lilly and Company and Innovent Biologics Group jointly announced that they had reached the following cooperation agreement on the rights of Eli Lilly's non-covalent (reversible) BTK inhibitor Jepali (pitumbrina 100 mg and 50 mg tablets) in mainland China: Innovent Biologics will be responsible for the import, sales, promotion and distribution of Jepali; Eli Lilly will be responsible for the research and development and post-marketing medical affairs of Jepali.

Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Taiwan's weighted index rose 2.6%, with semiconductor stocks leading the gains, and TSMC rising more than 4%
                            2024-12-23

                                    Tuanmaimai, the WeChat community group buying business under Meituan (03690.HK), issued an announcement stating that due to platform business adjustments, Tuanmaimai will cease operations from 24:00 on December 31, 2024.
                            2024-12-23

                                    Mao Yinian, Vice President of Meituan: Meituan has invested in several robot companies including Yushu and Galaxy General
                            2024-12-27

                                    A-share SMIC rose more than 5%
                            2024-12-27

                                    Meituan Vice President Mao Yinian: Meituan has obtained Dubai drone delivery commercial operation qualification
                            2024-12-27